Viral and host factors in the prediction of response to interferen-α therapy in chronic hepatitis C after long-term follow-up

Journal of Viral Hepatitis

Volumn 5, Issue 6, 1998, Pages 399-406

  Knolle, P A ^a,b   Kremp, S ^a   Hohler T ^a   Krummenauer, F ^a   Schirmacher, P ^a   Gerken, G ^a,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Hepatitis C virus; Interferon treatment; Long term outcome; Viral hepatitis

Indexed keywords

AMINOTRANSFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ARTICLE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HOST; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HLA-DR ANTIGENS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIREMIA;

EID: 0031740154     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00127.x     Document Type: Article

References (31)

1. Desmet VJ, Gerber M, Hoofnagle J, Manns M, Scheur PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatolagy 1994; 19: 1513-1520.
2. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994; 20: 349-355.
3. Gerken G, Pontisso P, Roggendorf M et al. Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol 1996; 24: 33-37.
4. Gerken G, Knolle P, Jakobs S, Meyer zum Büschenfelde K. Quantification and genotyping of serum HCV-RNA in patients with chronic hepatitis C undergoing interferon treatment. Arch Virol 1997; 142: 459-464.
5. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.
6. Bein G, Gläser R, Kirchner H. Rapid HLA-DRB1 genotyping by nested PCR amplification. Tissue Antigens 1992; 39: 68-73.
7. Höhler T, Gerken G, Notghi A et al. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 1997; 27: 259-264.
8. Breslow NE, Day NE. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. Iarc Sci Publ 1980; 1980: 5-338.
9. Inc. SISAS. Procedures Guide, 6th edn. North Carolina, USA: Cary, 1997.
10. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
11. Teuber G, Dienes HP, Meyer zum Büschenfelde K, Gerken G. Long-term follow-up of patients with chronic hepatitis C after interferon-alpha treatment. Digestion 1996; 57: 464-471.
12. Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenfelde K-H, Rittner C. A TNF-alpha promoter polymorphism is associated with chronic hepatitis B. Clin Exp Immunol 1998; 111: 579-582.
13. Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenfelde K-H, Rittner C. A tumor necrosis factor alpha promoter polymorphism at position-238 is associated with chronic active hepatitis C. J Med Virol 1998; 54: 173-177.
14. Chayama K, Tsubota A, Kobayashi M et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the out-come of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745-749.
15. Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hep Res Group Gastroenterol 1997; 113: 558-566.
16. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
17. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994; 75: 1361-1369.
18. Mizokami M, Lau JY, Suzuki K, Nakano T, Gojobori T. Differential sensitivity of hepatitis C virus quasispecies to interferon-alpha therapy. J Hepatol 1994; 21: 884-886.
19. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230.
20. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
21. Imamura H, Kawasaki S, Bandai Y, Sanjo K, Idezuki Y. Comparison between wedge and needle biopsies for evaluating the degree of cirrhosis. J Hepatol 1993; 17: 215-219.
22. Poynard T, Bedossa P, Opolon P. Natural history of liver flbrosis progression in patients with chronic hepatitis C. The OBSVIR, METAVIR, CLINIVIR, DOSVIR groups. Lancet 1997; 349: 825-832.
23. Löhr HF, Elste C, Dienes HP et al. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha. J Hepatol 1996; 25: 292-300.
24. Koziel MJ, Dudley D, Wong JT et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis [published erratum appears in J Immunol 1993 Mar 15; 150: 2563]. J Immunol 1992; 149: 3339-3344.
25. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98: 1432-1440.
26. Thursz MR. Host genetic factors influencing the outcome of hepatitis. J Viral Hep 1997; 4: 215-220.
27. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
28. Guidotti LG, Borrow P, Hobbs MV et al. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996; 93: 4589-4594.
29. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation [see comments]. J Inflamm 1995; 46: 32-41.
30. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
31. Ampurdanes S, Olmedo E, Maluenda MD et al. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatol 1996; 25: 827-832.